There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Applied DNA Sciences (APDN – Research Report), Kezar Life Sciences (KZR – Research Report) and Bolt Biotherapeutics (BOLT – Research Report) with bullish sentiments.
Applied DNA Sciences (APDN)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Applied DNA Sciences today and set a price target of $8.00. The company’s shares closed last Monday at $1.12, close to its 52-week low of $0.62.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Applied DNA Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
Kezar Life Sciences (KZR)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kezar Life Sciences, with a price target of $21.00. The company’s shares closed last Monday at $8.80.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kezar Life Sciences with a $21.00 average price target.
Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics received a Buy rating and an $8.00 price target from H.C. Wainwright analyst Edward White today. The company’s shares closed last Monday at $1.51, close to its 52-week low of $1.39.
According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Bolt Biotherapeutics is a Strong Buy with an average price target of $6.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APDN:
- H.C. Wainwright Sticks to Their Buy Rating for Awakn Life Sciences (AWKNF)
- Centerra Gold Announces Intention to make a Normal Course Issuer Bid
- Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference
- Acuity Brands Reports Fiscal 2022 Fourth-Quarter and Full-Year Results
- Centerra Gold Announces Highlights of New Life of Mine Plan for the Mount Milligan Mine, Including an Extension of Mine Life to 2033